| David Mizrachi, MD | |
|
5301 S Congress Ave, Palm Beach Radiology Professionals, Atlantis, FL 33462-1149 | |
| (561) 548-1230 | |
| (561) 548-1283 |
| Full Name | David Mizrachi |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 22 Years |
| Location | 5301 S Congress Ave, Atlantis, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245421692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD428446 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Delray Medical Center | Delray beach, FL | Hospital |
| Good Samaritan Medical Center | West palm beach, FL | Hospital |
| St Mary's Medical Center | West palm beach, FL | Hospital |
| West Boca Medical Center | Boca raton, FL | Hospital |
| St Lucie Medical Center | Port saint lucie, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fands Radiology Pc | 0244368868 | 101 |
| Florida United Radiology Lc | 9537156757 | 79 |
| Jupiter Imaging Associates Inc | 5294629135 | 57 |
| Radiology Physician Solutions Of Florida Llc | 3870716731 | 87 |
| Radiology Physician Solutions Of West Florida Llc | 3577876218 | 96 |
| Sheridan Radiology Services Of Central Florida Inc | 4688762149 | 109 |
| Sheridan Radiology Services Of Pinellas Inc | 7517119407 | 82 |
| Sheridan Radiology Services Of South Florida Inc | 7517000847 | 43 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Jupiter Imaging Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932156767 PECOS PAC ID: 5294629135 Enrollment ID: O20040211000512 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Sheridan Radiology Services Of Central Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134567506 PECOS PAC ID: 4688762149 Enrollment ID: O20071116000118 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Florida United Radiology Lc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407809395 PECOS PAC ID: 9537156757 Enrollment ID: O20080627000517 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Sheridan Radiology Services Of South Florida Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972851129 PECOS PAC ID: 7517000847 Enrollment ID: O20100311000833 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Sheridan Radiology Services Of Pinellas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083007454 PECOS PAC ID: 7517119407 Enrollment ID: O20121128000124 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Radiology Physician Solutions Of Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356767651 PECOS PAC ID: 3870716731 Enrollment ID: O20140521001511 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | F&s Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518299957 PECOS PAC ID: 0244368868 Enrollment ID: O20140731002204 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Radiology Physician Solutions Of West Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104205046 PECOS PAC ID: 3577876218 Enrollment ID: O20150723008463 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Proscan Nch Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003406711 PECOS PAC ID: 6103233051 Enrollment ID: O20210322001326 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Entity Name | Concord Radiology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598260515 PECOS PAC ID: 8628332061 Enrollment ID: O20210416001599 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Mizrachi, MD 5301 S Congress Ave, Avepalm Beach Radiology Professionals, Atlantis, FL 33462-1149 Ph: (561) 548-1230 | David Mizrachi, MD 5301 S Congress Ave, Palm Beach Radiology Professionals, Atlantis, FL 33462-1149 Ph: (561) 548-1230 |
News Archive
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A new optical method that can image subsurface structures under skin has been demonstrated by scientists at the National Institute of Standards and Technology (NIST) and the Johns Hopkins University Applied Physics Laboratory.
A sizzling genetic discovery by Chinese scientists may one day allow pig tissue to be transplanted successfully into humans. Their research presented in the Journal of Leukocyte Biology (http://www.jleukbio.org) represents a major step forward toward filling the shortage of vital organs for human transplantation.
At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.
› Verified 7 days ago
Michael J Cohen, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 | |
Noa Ann Beck, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 | |
Mehdi Bathaii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 Fax: 561-548-1238 | |
Dr. Matthew Phillip Brill, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-601-9191 | |
Marat Bakman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 Fax: 561-548-1238 | |
Steven Martin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5301 S Congress Ave, Atlantis, FL 33462 Phone: 561-548-3727 Fax: 561-548-1238 |